The potential of peptide immunotherapy in allergy and asthma.

被引：8

作者：

Ali F.R. ^{[1
]}

Kay A.B. ^{[1
]}

Larché M. ^{[1
]}

机构：

[1] Department of Allergy and Clinical Immunology, Faculty of Medicine, Imperial College, National Heart and Lung Institute, Dovehouse Street, London

来源：

Current Allergy and Asthma Reports | 2002年 / 2卷 / 2期

基金：

英国医学研究理事会;

关键词：

Major Histocompatibility Complex; Allergy Clin Immunol; Cell Anergy; House Dust Mite Allergen; Late Asthmatic Reaction;

D O I：

10.1007/s11882-002-0010-5

中图分类号：

学科分类号：

摘要：

Allergic conditions contribute significantly to the burden of chronic disease in the industrialized world. Current treatments offer varying degrees of palliation. The sole proven disease-modifying strategy, specific or whole-allergen immunotherapy, is limited because of the associated risk of systemic adverse effects, such as anaphylaxis. Short, linear allergen-derived peptides, corresponding to T cell epitopes, offer the possibility of a safer approach as they are capable of inducing allergen-specific hyporesponsiveness without cross-linking mast cell-bound IgE. This review evaluates the scientific basis of peptide immunotherapy and clinical experience in allergy up to the present time.

引用

页码：151 / 158

页数：7

共 136 条

[31]

Robinson DS(1999)The safety and efficacy of ALLERVAX CAT in cat-allergic patients Clin Immunol 93 222-231

[32]

Ying S(1998)Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom J Allergy Clin Immunol 101 747-754

[33]

Bentley AM(1998)Role of interleukin-10 in specific immunotherapy J Clin Invest 102 98-106

[34]

Kay AB(1999)IgE-independent MHC-restricted T cell peptide epitope-induced late asthmatic reactions J Exp Med 189 1885-1894

[35]

Karin N(2001)Allergen-derived T-cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects J Immunol 167 1734-1739

[36]

Binah O(2001)A dosing protocol of allergen-derived T-cell peptide epitopes for the treatment of allergic disease [abstract] J Allergy Clin Immunol 107 716-716

[37]

Grabie N(2001)A double-blind, placebo-controlled study of short peptides derived from Fel d 1 in cat-allergic subjects [abstract] J Allergy Clin Immunol 107 711-711

[38]

Warren KG(1996)A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells J Exp Med 183 2669-2674

[39]

Catz I(1996)Induction and characterisation of TGFb secreting Th3 cells FASEB J 10 A1444-A1444

[40]

Wucherpfennig KW(1996)Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro J Clin Invest 98 1676-1683

← 1 2 3 4 5 6 7 8 9 10 →